Watching HIV bud from cells: Study shows last-minute role of protein named ALIX

May 16, 2014, University of Utah
The top row shows, left to right, red-labeled protein molecules named Gag (shown here in black and white) assembling to form a new HIV particle that buds from a human cell grown in the laboratory. The bottom row shows the same process but with proteins named ALIX labeled green (also in black and white). Together, the two sequences (minutes and seconds shown at top) show how ALIX gets involved late in the process as Gag assembles to form a new particle of HIV, which causes AIDS. That finding of a new University of Utah study contradicts earlier research that had suggested ALIX gets involved at an earlier stage in the HIV budding process. Credit: Pei-I Ku, University of Utah.

University of Utah researchers devised a way to watch newly forming AIDS virus particles emerging or "budding" from infected human cells without interfering with the process. The method shows a protein named ALIX gets involved during the final stages of virus replication, not earlier, as was believed previously.

"We watch one cell at a time" and use a digital camera and special microscope to make movies and photos of the budding process, says virologist Saveez Saffarian, an assistant professor of physics and astronomy and senior author of a new study of HIV budding published online today in the Public Library of Science journal PLOS ONE.

"We saw ALIX recruited into HIV budding for the first time," he says. "Everybody knew ALIX is involved in HIV budding, but nobody could visualize the recruitment of ALIX into the process."

The finding is "fundamental basic science" and has no immediate clinical significance for AIDS patients because ALIX is involved in too many critical functions like cell division to be a likely target for new medications, Saffarian says.

"We know a lot about the proteins that help HIV get out of the cell, but we do not know how they come together to help the virus get out, and it will be in the next 10 to 20 years that we will know a lot more of about this mechanism," he adds. "Would this be a drug target? Would this be a part of biochemistry used in a therapeutic or biotech industry later on? I can't tell you now. But if it was not because of our curiosity as a species, we would not have the technology we have today."

The new study "is nice work," says HIV budding expert Wes Sundquist, who advised Saffarian and is professor and co-chair of biochemistry at the University of Utah School of Medicine. "It's of genuine interest for those of us who study the mechanism of HIV assembly."

The study was funded by the National Science Foundation. Saffarian conducted the study with first author, Pei-I Ku, a University of Utah doctoral student in physics; Mourad Bendjennat, a postdoctoral fellow in physics and astronomy; technician Jeff Ballew; and Michael Landesman, another postdoctoral fellow in physics and astronomy who previously worked in Sundquist's biochemistry lab.

Watch, Don't Touch, as HIV Buds

Biochemical methods used for years involve collecting millions of viruses in lab glassware and doing different analyses to reveal the proteins that make up the virus – for example, by using antibodies that bind to certain proteins and using other proteins that make the first proteins fluoresce so they can be seen.

"You're not doing it one virus at a time," Saffarian says. "The problem with that is you don't see the differences among similar viruses. And you do not see the timing of how various proteins come and go to help the virus get out of the cell."

Other methods freeze or otherwise fix as new HIV particles emerge from them, and use an electron microscope to photograph those freeze-frame views of viral replication. Saffarian also uses technology known as "total internal reflection fluorescence microscopy," which has been used to look at dynamic processes in cells.

A 10-second video showing HIV budding with ALIX

The method was used before to make images of the budding of HIV and a similar horse virus, EIAV. But Saffarian says that study didn't show ALIX getting involved in HIV budding, and had flaws that wrongly indicated the ALIX got involved quite early in the EIAV budding process, suggesting it did the same in HIV budding.

Ku, Saffarian and colleagues combined that microscopy method with an improved way of genetically linking a green fluorescent "label" to ALIX proteins in cloned cells so they can see the proteins without harming their normal function. The researchers tried numerous so-called "linkers" and found the one that let them see the ALIX proteins as they got involved in HIV budding but without disturbing the process.

Neither the microscope technology nor labeling proteins with green fluorescence are new, but "what we did that is new is we linked these fluorescence proteins to ALIX using many different kinds of linkers" to find one that let the ALIX protein function properly, he adds.

The problem with earlier research – which indicated ALIX was involved early in the budding process – was that only one linker was used, and it impaired ALIX' normal function, Saffarian says.

University of Utah physics doctoral student Pei-I Ku prepares a sample for the digital microscope she uses to make movies and photographs of the AIDS-causing human immunodeficiency virus budding from human cells in the laboratory. The microscope is in a glass chamber to keep the cells at body temperature so researchers can watch the process over time. Ku is the first author of a new study in which University of Utah researchers combined imaging technology and biochemistry to make such images. The method revealed that a protein named ALIX gets involved in the process later than believed previously. Credit: Tom Bear, for the University of Utah.

Looking at Proteins Forming HIV

When HIV replicates inside a human cell, a protein named Gag makes up most of the new particles – there are 4,000 copies of the Gag protein in one HIV particle – although a bunch of other proteins get involved in the process, including ALIX, which stands for "alg-2 interacting protein x." Experiments like those by Saffarian's team use "virus-like particles," which are HIV particles stripped of their genetic blueprint or genome so they don't pose an infection risk in the lab.

"Virus-like particles maintain the same geometry and same budding process as infectious HIV," Saffarian says.

During budding, Gag proteins assemble on the inside of a cell membrane – along with ALIX in the late stages – and form a new HIV particle that pushes its way out of the cell – the process by which AIDS in an infected person spreads from cell to cell.

To look at the budding process, Ku, Saffarian and colleagues place human HELA cells containing the particles in a small amount of liquid growth medium in a petri dish and put it under the microscope, which is in a glass chamber kept at body temperature so the cells can remain alive for more than 48 hours. A solid-state blue laser is aimed at the sample to make the green-labeled ALIX and red-labeled Gag proteins glow or fluoresce so they can be seen as they assemble into a virus particle.

With red-labeled Gag proteins and green-labeled ALIX proteins, "we could see ALIX come at the end of the assembly of the virus particle," with some 100 ALIX proteins converging with the roughly 4,000 Gag molecules and assembling into a new HIV particle. ALIX then brings in two other proteins, which cut the budding virus particle off from the cell when it emerges. ALIX' position during the pinching off of new particles hadn't been recognized before, Saffarian says

The researchers watched the virus particles bud from one cell at a time: usually about 100 of them emerged during a two-hour period. Saffarian says most of the ALIX proteins left when HIV assembly was complete and returned to the liquid inside a cell.

He says the discovery that ALIX doesn't get involved until the late stages of HIV budding suggests the existence of a previously unrecognized mechanism in the virus that regulates the timing of ALIX and other proteins in assembling new HIV particles.

"We discovered that the cellular components that help with the release of the actually arrive in a much more complex timing scheme than predicted based on the biochemical data," Saffarian says. "The outcome of this study is promising because it uncovers a new regulatory mechanism for recruitment of cellular components to the HIV budding sites and opens the door to exciting future studies on the mechanism of HIV budding."

Physicists in Virology

Why are physicists studying viruses? First, biophysicists study physical mechanisms in biology, such as motors in cells. Saffarian earned a doctorate in biophysics, developing methods that used fluorescent light to look at cellular processes.

"I got very jealous because I felt every time I contributed to a project, the actual science was somebody else's pursuit," he says. "I was helping them with tools, but not asking fundamental questions myself."

So Saffarian did a postdoctoral fellowship in cell biology at Harvard Medical School, then "decided I wanted to study viruses, how they get out of cells and replicate." In addition to his position in physics, he is an adjunct assistant professor of biology.

Explore further: Research identifies compounds that control hemorrhagic viruses

Related Stories

Research identifies compounds that control hemorrhagic viruses

May 1, 2014
People fear diseases such as Ebola, Marburg, Lassa fever, rabies and HIV for good reason; they have high mortality rates and few, if any, possible treatments. As many as 90 percent of people who contract Ebola, for instance, ...

Seeing through HIV's disguises: Researchers identify 25 human proteins that may be crucial for HIV-1 infection

February 27, 2013
Studying HIV-1, the most common and infectious HIV subtype, Johns Hopkins scientists have identified 25 human proteins "stolen" by the virus that may be critical to its ability to infect new cells. HIV-1 viruses capture many ...

Coral reefs provide potent new anti-HIV proteins

April 29, 2014
Researchers have discovered a new class of proteins capable of blocking the HIV virus from penetrating T-cells, raising hope that the proteins could be adapted for use in gels or sexual lubricants to provide a potent barrier ...

Kinesin 'chauffeur' helps HIV escape destruction

October 22, 2012
A study in The Journal of Cell Biology identifies a motor protein that ferries HIV to the plasma membrane, helping the virus escape from macrophages.

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.